Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275153 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL8432806 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL4275670 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL4280436 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL4271908 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL10384073 | 1.00 | DNM1 (0.40) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL11520008 | 0.93 | DNM1 (0.36) | DNM1THRBTSHRMEN1HTT | |
| SCHEMBL9124092 | 0.90 | ADRB2 (0.39) | DNM1THRBTSHRALDH1A1CA1 | |
| SCHEMBL927971 | 0.84 | LMNA (0.44) | THRBTSHRMEN1HTTKMT2A | |
| SCHEMBL926386 | 0.84 | LMNA (0.44) | THRBTSHRMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608877-A1 | VARIANT RNA-GUIDED CAS12F4 NUCLEASES AND DNA BINDING PROTEINS | Inari Agriculture Technology, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024091775-A1 | VARIANT RNA-GUIDED CAS12F4 NUCLEASES AND DNA BINDING PROTEINS | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024030437-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMER METHODS AND COMPOSITIONS | PMIDG, LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024008967-A1 | LIPID NANOPARTICLES COMPRISING AN IMIDAZOLIUM-BASED CATIONIC LIPID | POLYPLUS TRANSFECTION (FR) | 2024-01-11 | — | — | WO | disclosed |
| EP-3935156-A1 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3625342-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | The Broad Institute, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3455357-A1 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | The Broad Institute Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2018213726-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | THE BROAD INSTITUTE, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2017219027-A1 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | The Broad Institute Inc. (US) | 2017-12-21 | — | — | WO | disclosed |
| US-9636302-B2 | Lipids and compositions for intracellular delivery of biologically active compounds | AXOLABS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20160324781-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2016-11-10 | — | — | US | disclosed |
| WO-2016079197-A1 | DELIVERY ENHANCERS FOR CONJUGATED SIRNA AND LIPID NANOPARTICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-05-26 | — | — | WO | disclosed |
| US-20160090593-A1 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR) | ALNYLAM PHARMACEUTICALS, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20160076029-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | ALNYLAM PHARMACEUTICALS, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20150050295-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | AXOLABS GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20140288154-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140170175-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | AXOLABS GMBH (DE) | 2014-06-19 | — | — | US | disclosed |
| EP-2496238-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | Alnylam Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056883-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN (TTR) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | ALNYLAM PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050295-A9 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, NPC1L1, PLIN3 | DNM1 408/4885THRB 3881/4885TSHR 4444/4885 |
| US-20140288154-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes | KIF5A, KIF5C, KIF11 | DNM1 561/4885THRB 4754/4885TSHR 4813/4885 |
| US-20160076029-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | TTR, CRYAA, SARNP | DNM1 2320/4885THRB 335/4885TSHR 547/4885 |
| US-20140170175-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, NPC1L1, PLIN3 | DNM1 408/4885THRB 3881/4885TSHR 4444/4885 |
| US-20160324781-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, NPC1L1, PLIN3 | DNM1 408/4885THRB 3881/4885TSHR 4444/4885 |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | KIF5A, KIF5C, KIF11 | DNM1 561/4885THRB 4754/4885TSHR 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.